Bepridil (CERM-1978) blockade of action potentials in cultured rat aortic smooth muscle cells

European Journal of Pharmacology
S Mras, N Sperelakis

Abstract

Reaggregate cultures (primary) were prepared from enzyme-dispersed vascular smooth muscle (VSM) cells from rat aortas. The cultures were incubated for 7-10 days, and then studied by the intracellular microelectrode technique. The cells were electrically quiescent (mean resting potential of --47 mV), and extracellular electrical stimulation usually did not elicit a membrane response. Addition of 10 mM tetraethylammonium rapidly induced excitability, allowing the VSM cells to fire Ca2+-dependent action potentials in response to electrical stimulation. The electrical responses often had two components, an initial spike and a later plateau-like component. The action potential spikes had a mean amplitude of 22 mV but occasionally were overshooting; the plateaus had a mean duration (at 50% repolarization) of 3.8 sec. A new anti-anginal agent, bepridil (10(-8)-10(-5) M), depressed the amplitude and duration of the plateau and blocked the spike component of the action potential in a dose-dependent fashion without affecting the resting potential. This finding is consistent with the view that bepridil acts as a Ca2+-antagonistic agent to prevent the generation of the action potentials, and this action can explain its antianginal properties.

References

Jan 1, 1972·Pflügers Archiv : European journal of physiology·M KohlhardtA Fleckenstein
May 1, 1974·European Journal of Pharmacology·M J McLeanN Sperelakis
Jan 1, 1980·Journal of Cardiovascular Pharmacology·K A Kane, E Winslow

❮ Previous
Next ❯

Citations

Nov 1, 1981·Pflügers Archiv : European journal of physiology·E Zelcer, N Sperelakis
Jul 16, 1982·European Journal of Pharmacology·D C Pang, N Sperelakis
Nov 19, 1986·European Journal of Pharmacology·E WinslowR J Marshall
Nov 24, 1987·European Journal of Pharmacology·J M Ousterhout, N Sperelakis
Jan 1, 1983·Pharmacology & Therapeutics·W G Nayler, J D Horowitz
Jan 1, 1987·Comparative Biochemistry and Physiology. B, Comparative Biochemistry·B Lucas-HeronC Leoty
Nov 15, 2000·Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine·M FringsM Diener
Jun 1, 1984·The American Journal of Cardiology·A SassineP Puech
Oct 1, 1990·Biochemical Pharmacology·M ConstantinR Massingham
Jan 15, 1983·Biochemical Pharmacology·G Cramb, J W Dow
Jan 1, 1988·Annals of the New York Academy of Sciences·T Godfraind
May 1, 1985·Hypertension·R W AlexanderS E Rittenhouse
May 1, 1986·British Journal of Pharmacology·P A Molyvdas, N Sperelakis
Apr 15, 1984·Biochemical Pharmacology·A Younes, J M Schneider
May 9, 1989·Biochimica Et Biophysica Acta·G J KaczorowskiM L Garcia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.